Zota Health Care Q4 FY26 Results: Loss Rs 14 Cr

Zota Health Care Q4 FY26 results were declared on May 22, 2026. The company reported net loss of Rs 14 crore for the quarter ended March 31, 2026, down 7.7% YoY compared to loss of Rs 13 crore in Q4 FY25. Revenue stood at Rs 163 crore, for the quarter ended March 31, 2026. Results are on a Consolidated basis. Zota Health Care is a Pharmaceuticals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Zota Health Care Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	Rs 163 crore	Rs N/A crore	N/A
Net Loss	14	13	-7.7%
Basis	Consolidated

Note: Zota Health Care Q4 FY26 results declared May 22, 2026. Data sourced from Screener.in/BSE filings. Verify from audited filings before investment decisions.

Zota Health Care Q4 FY26 Performance Analysis

The Zota Health Care Q4 FY26 results reflect the company’s performance in the January to March 2026 quarter. The quarter reflects near-term profitability challenges. Zota Health Care operates in the Pharmaceuticals segment, benefiting from India’s GDP growth above 6.5% and domestic demand conditions in FY26.

Revenue of Rs 163 crore was for the quarter ended March 31, 2026. Steady revenue reflects consistent business conditions.

Screen the best stocks on the Univest Screener.

Key Factors Driving Zota Health Care Q4 FY26 Results

Revenue and Business Performance

Revenue of Rs 163 crore in Zota Health Care Q4 FY26 was for the quarter ended March 31, 2026. Stable revenue momentum reflects consistent operational delivery. The January to March 2026 quarter is the year-end quarter for Indian companies, characterised by strong order execution and fiscal year-end activity.

Profitability and Margin Trends

The Zota Health Care Q4 FY26 net loss of Rs 14 crore down 7.7% YoY. The net loss reflects ongoing operational challenges. Cost rationalisation and revenue recovery remain management priorities for FY27.

India Macro Environment Q4 FY26

India’s macro environment in Q4 FY26 was supportive, with GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption. The RBI’s accommodative stance supported credit and demand conditions. For Zota Health Care operating in the Pharmaceuticals sector, these macro tailwinds provided a constructive backdrop entering FY27.

FY27 Outlook

Following the firm results, management guidance on FY27 revenue trajectory, margin improvement, and capital allocation will be key investor watchpoints. The Pharmaceuticals sector continues to benefit from India’s structural growth drivers including urbanisation, infrastructure investment, and rising middle-class consumption.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the company

Investments in securities are subject to market risk. This content is for educational purposes only. Verify from BSE/NSE filings. Consult a SEBI-registered financial advisor.